fibrinopeptide-a has been researched along with Retinal-Diseases* in 2 studies
2 other study(ies) available for fibrinopeptide-a and Retinal-Diseases
| Article | Year |
|---|---|
Coagulation and platelet activation after retinal vein occlusions.
The role played by coagulation and platelet activation in the pathogenesis of retinal vein occlusions (RVO) has been evaluated by measuring beta-thromboglobulin (B-TG), circulating platelet aggregates (CPA), thromboxane B2 (TxB2) and fibrinopeptide A (FPA) in 25 patients less than 40 years old, investigated after the acute phase of RVO. FPA nd B-TG were significantly higher than in healthy subjects; CPA and TxB2 were not different. These abnormalities, found in patients free from apparent generalized vascular disease, suggest that a thrombophilic state characterized by coagulation and platelet activation is present in a high proportion of young patients with RVO. Topics: Adolescent; Adult; beta-Thromboglobulin; Blood Coagulation; Blood Platelets; Female; Fibrinopeptide A; Humans; Ischemia; Male; Platelet Aggregation; Retina; Retinal Diseases; Retinal Vein; Thromboxane B2 | 1982 |
Determination of human fibrinopeptide A by radioimmunoassay in purified systems and in the blood.
The formation of fibrin clots or circulating soluble fibrin is accompanied by the appearance of fibrinopeptides. Measurement of the fibrinopeptide concentration in plasma can provide important information on the rate of conversion of fibrinogen to fibrin by thrombin. This rate varies under different physiologic and pathologic conditions. Fibrinopeptide A is a better molecular marker of the conversion than fibrinopeptide B since it is the first peptide to be cleaved by thrombin. A radioimmunoassay technique has been developed for the quantitative determination of human fibrinopeptide A. The procedure detects human fibrinopeptide A at a concentration of approximately 0.05 ng/ml. The variation of fibrinopeptide A content in normal persons may reflect its rapid formation and catabolism. A significantly increased concentration of this peptide was found in a patient during defibrination therapy with a purified enzyme from the venom of Agkistrodon rhodostoma and in patients suffering from retinal vascular occlusions. Topics: Amino Acid Sequence; Batroxobin; Fibrinogen; Fibrinopeptide A; Humans; Immune Sera; Protein Binding; Radioimmunoassay; Retinal Diseases; Retinal Vessels; Thrombophlebitis; Thrombosis; Tyrosine | 1975 |